Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × OTHER × Postoperative Complications × Clear all

Phase

Phase NA 96 Phase 3 8 Phase 4 7 Phase 2 5 Phase 2/3 3 Phase 1 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 291 Leukemia, Myeloid, Acute 236 Multiple Myeloma 208 Carcinoma, Non-Small-Cell Lung 197 Prostatic Neoplasms 189 Neoplasms 178 Lymphoma 174 Melanoma 165 Colorectal Neoplasms 165 Leukemia 160 Precursor Cell Lymphoblastic Leukemia-Lymphoma 144 Pancreatic Neoplasms 143 Recurrence 135 Lung Neoplasms 134 Glioblastoma 123 Neoplasm Metastasis 122 Lymphoma, Non-Hodgkin 116 Ovarian Neoplasms 113 Leukemia, Lymphocytic, Chronic, B-Cell 105 Myelodysplastic Syndromes 104 Lymphoma, Large B-Cell, Diffuse 97 Lymphoma, Mantle-Cell 94 Carcinoma, Hepatocellular 90 Lymphoma, Follicular 85 Stomach Neoplasms 84 Brain Neoplasms 84 Hodgkin Disease 82 Carcinoma, Renal Cell 80 Sarcoma 75 Burkitt Lymphoma 66

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02943694 2016-10-25

FSI-TaTME

Ruijin Hospital

Phase 1/2 Unknown

Postoperative Complications

Data powered by HemOnc (CC BY 4.0) Colophon ⚡